A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A RANDOMIZED PHASE 3 STUDY OF THE COMBINATION OF PEMBROLIZUMAB (MK-3475) PLUS EPACADOSTAT (INCB024360) ALONE OR WITH PLATINUM-BASED CHEMOTHERAPY VERSUS PEMBROLIZUMAB PLUS PLATINUM-BASED CHEMOTHERAPY PLUS PLACEBO AS FIRST-LINE TREATMENT IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER

Intervention/treatment:
KEYTRUDA / EPACADOSTAT
Medical condition:
NON-SMALL CELL LUNG CANCER
Protocol code:
715/ECHO-306
Control number:
211384
Status:
Closed
Approved:
December 20, 2017
Date Completed:
Trial phase:
Phase 2
For more information:
ClinicalTrials.gov - NCT03322566
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Study Director
Organization
Incyte Corporation
Phone:
855-463-3463
Sponsor
INCYTE CORPORATION

Locations

British Columbia

BCCA-Cancer Centre of the Southern Interior
Kelowna, British Columbia, V1Y 5L3
Lions Gate Hospital
North Vancouver, British Columbia, V7L 2L7

Quebec

CHU de Quebec - Hotel-Dieu de Quebec
Québec, Quebec, G1R 2J6
CISSS de la Monteregie-Centre
Greenfield Park, Quebec, J4V 2H1
CIUSSS de la Mauricie-et-du-Centre-du-Quebec
Trois-Rivières, Quebec, G8Z 3R9
CIUSSS du Nord-de-l'ILe-de-Montreal Hopital du Sacre-Coeur de Montreal
Montreal, Quebec, H4J 1C5
CIUSSS Ouest de l'Ile - St-Mary's Hospital
Montreal, Quebec, H3T 1M5
CSSS de Laval- Hopital de la Cite de la Sante
Laval, Quebec, H7M 3L9

Results

See the results from the trial NCT03322566. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?